Cost-Effectiveness Of The SQ^® Grass SLIT-Tablet In Children With Allergic Rhinitis: A German Payer Perspective.

The trial showed that a numerically lower proportion of patients in the SQ grass SLIT-tablet arm were diagnosed with asthma (34/398 or 8.54%) than the placebo arm (39/414 or 9.42%), but the finding did not reach statistical significance (hazard ratio 0.9; p=0.667). 10 While the primary endpoint was not statistically significant, treatment with the SQ grass SLIT-tablet did significantly reduce the odds of experiencing asthma symptoms or using asthma medication at the end of trial (i.e. after 3 years of treatment and 2 years of follow-up) relative to placebo with an odds ratio of 0.66 (p=0.036). 10 Furthermore, relative to the placebo arm, AR symptoms were reduced by between 22% and 30% in each year of the trial (p≤0.002 for all 5 years).

also in 111,027 other papers